SF3B1
Chr 2splicing factor 3b subunit 1
This gene encodes subunit 1 of the splicing factor 3b protein complex, which is essential for pre-mRNA splicing by recognizing branch sites and anchoring U2 snRNP to pre-mRNA during spliceosome assembly. The gene is extremely intolerant to loss-of-function variants (pLI ~1.0, LOEUF 0.066), suggesting that heterozygous mutations would likely cause severe developmental disorders, though specific Mendelian phenotypes have not yet been established in OMIM. Currently, SF3B1 mutations are only documented in somatic myelodysplastic syndrome, but the high constraint scores indicate this gene may be associated with uncharacterized neurodevelopmental conditions.
Some data sources returned errors (1)
ncbi: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Among the most LoF-intolerant genes (~top 3%)
Extremely missense-constrained (top ~0.01%)
The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).
Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
SF3B1 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
3D Protein StructureAlphaFold
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITINGLuspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
ACTIVE NOT RECRUITINGImpact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
RECRUITINGMonitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples
RECRUITINGPatient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
ACTIVE NOT RECRUITINGExternal Resources
Links to major genomics databases and tools